Denali Therapeutics (DNLI) Operating Leases (2019 - 2025)
Historic Operating Leases for Denali Therapeutics (DNLI) over the last 7 years, with Q3 2025 value amounting to $38.8 million.
- Denali Therapeutics' Operating Leases fell 1713.94% to $38.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.8 million, marking a year-over-year decrease of 1713.94%. This contributed to the annual value of $36.7 million for FY2024, which is 1847.0% down from last year.
- Denali Therapeutics' Operating Leases amounted to $38.8 million in Q3 2025, which was down 1713.94% from $41.0 million recorded in Q2 2025.
- Over the past 5 years, Denali Therapeutics' Operating Leases peaked at $67.8 million during Q1 2021, and registered a low of $36.7 million during Q4 2024.
- Its 5-year average for Operating Leases is $53.4 million, with a median of $53.9 million in 2023.
- As far as peak fluctuations go, Denali Therapeutics' Operating Leases crashed by 489.87% in 2022, and later plummeted by 1847.0% in 2024.
- Quarter analysis of 5 years shows Denali Therapeutics' Operating Leases stood at $58.6 million in 2021, then fell by 9.43% to $53.0 million in 2022, then fell by 15.18% to $45.0 million in 2023, then dropped by 18.47% to $36.7 million in 2024, then grew by 5.94% to $38.8 million in 2025.
- Its last three reported values are $38.8 million in Q3 2025, $41.0 million for Q2 2025, and $43.0 million during Q1 2025.